Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

Benekli M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T., Sevinc A., ÇABUK D., ...More

ONCOTARGETS AND THERAPY, vol.8, pp.1-5, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2015
  • Doi Number: 10.2147/ott.s70670
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1-5
  • Keywords: advanced thyroid cancer, sorafenib, overall survival, PHASE-II TRIAL, ENDOTHELIAL GROWTH-FACTOR, DOUBLE-BLIND, INHIBITORS, CARCINOMA
  • Gazi University Affiliated: Yes


Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication.